Northern Trust Corp Acquires 23,572 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Northern Trust Corp raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 262,263 shares of the company's stock after acquiring an additional 23,572 shares during the quarter. Northern Trust Corp owned about 0.91% of Krystal Biotech worth $41,086,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in KRYS. Wilmington Savings Fund Society FSB bought a new position in shares of Krystal Biotech during the 3rd quarter worth about $40,000. Covestor Ltd grew its holdings in shares of Krystal Biotech by 972.7% in the fourth quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after acquiring an additional 642 shares in the last quarter. Avanza Fonder AB bought a new position in Krystal Biotech during the fourth quarter valued at about $119,000. KBC Group NV increased its stake in shares of Krystal Biotech by 46.3% during the 4th quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Krystal Biotech by 74.4% in the fourth quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after buying an additional 433 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Guggenheim cut their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday. Chardan Capital reiterated a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a research report on Wednesday. Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, May 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech currently has an average rating of "Buy" and a consensus target price of $218.63.

Krystal Biotech Price Performance

KRYS stock traded down $4.94 during midday trading on Friday, reaching $132.23. The company had a trading volume of 329,798 shares, compared to its average volume of 300,407. The firm has a 50-day moving average price of $171.56 and a 200-day moving average price of $170.04. The company has a market capitalization of $3.82 billion, a P/E ratio of 44.22 and a beta of 0.79. Krystal Biotech, Inc. has a 1 year low of $131.71 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). The firm had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. On average, equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).